{"protocolSection":{"identificationModule":{"nctId":"NCT05461131","orgStudyIdInfo":{"id":"IB-202P"},"organization":{"fullName":"ILiAD Biotechnologies","class":"INDUSTRY"},"briefTitle":"Pertussis Challenge Study in Adults Vaccinated With BPZE1","officialTitle":"A Phase 2b, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess Protection Against Colonization Following Challenge With Virulent Wild-Type Bordetella Pertussis","acronym":"CHAMPION-1"},"statusModule":{"statusVerifiedDate":"2025-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-06-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-07-25","type":"ACTUAL"},"completionDateStruct":{"date":"2023-10-26","type":"ACTUAL"},"studyFirstSubmitDate":"2022-07-13","studyFirstSubmitQcDate":"2022-07-13","studyFirstPostDateStruct":{"date":"2022-07-15","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-10-24","resultsFirstSubmitQcDate":"2025-03-05","resultsFirstPostDateStruct":{"date":"2025-03-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-03-05","lastUpdatePostDateStruct":{"date":"2025-03-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"ILiAD Biotechnologies","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a randomised, double-blinded, placebo-controlled trial of BPZE1 that includes virulent B. pertussis challenge followed by a safety follow-up.","detailedDescription":"This Phase 2b challenge study will investigate colonisation rates, immunologic response, and the safety of BPZE1 vaccination to potentially protect against colonising, virulent wild-type B. pertussis infection in healthy adults using a virulent challenge model. Consenting, eligible participants will receive a single dose of BPZE1 or placebo. 2-4 months later they will be challenged with B. pertussis and admitted to a challenge unit. Participants will remain in the challenge unit for a total of 17 days and 16 nights during which time they will be monitored closely. If a participant develops symptoms of pertussis (per investigator discretion), antibiotic (azithromycin) will be started and the participant will remain in the unit for 3 additional days of observation before discharge. If symptoms of pertussis do not develop, then participants will receive antibiotic (azithromycin) from Days 14-16 of the challenge unit stay. Participants will undergo safety follow-up for at least 6 months post-vaccination and at least 3 months post-challenge, for a total follow-up of 6-7 months."},"conditionsModule":{"conditions":["Pertussis/Whooping Cough","Bordetella Pertussis, Whooping Cough"],"keywords":["Bordetella Pertussis","BPZE1","Vaccine","Live Attenuated Vaccine","Challenge Study"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":53,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"BPZE1","type":"EXPERIMENTAL","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. Pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.","interventionNames":["Biological: BPZE1","Drug: Azithromycin","Other: Bordetella Pertussis Challenge Strain"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. Pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.","interventionNames":["Biological: Placebo","Drug: Azithromycin","Other: Bordetella Pertussis Challenge Strain"]}],"interventions":[{"type":"BIOLOGICAL","name":"BPZE1","description":"Live attenuated vaccine","armGroupLabels":["BPZE1"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Placebo","armGroupLabels":["Placebo"]},{"type":"DRUG","name":"Azithromycin","description":"Antibiotic","armGroupLabels":["BPZE1","Placebo"]},{"type":"OTHER","name":"Bordetella Pertussis Challenge Strain","description":"Challenge Strain","armGroupLabels":["BPZE1","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants Colonized Following Virulent Challenge","description":"Participants by treatment group (BPZE1 and placebo) colonized on any day (Challenge Day 9, 11 or 14) following virulent challenge as determined by culture.","timeFrame":"Challenge Day 9, 11 or 14"}],"secondaryOutcomes":[{"measure":"GMFR of Mucosal Anti-pertussis S-IgA Antibody","description":"The geometric mean fold rise (GMFR) of mucosal anti-pertussis S-IgA antibody (whole cell extract \\[WCE\\], FHA, PRN, PT and fimbriae types 2 and 3 \\[FIM2/3\\]) from baseline to Day 28 (BPZE1 and placebo). Secretory IgA to be normalized (\\[specific S-IgA\\]/\\[total S-IgA\\])","timeFrame":"Day 28"},{"measure":"GMFR of Serum IgA Antibody","description":"The GMFR of serum IgA antibody (WCE, FHA, PRN, PT and FIM2/3) from baseline to Day 28 (BPZE1 and placebo)","timeFrame":"Day 28"},{"measure":"GMFR of Serum IgG Antibody","description":"The GMFR of serum IgG antibody (WCE, FHA, PRN, PT and FIM2/3) from baseline to Day 28 (BPZE1 and placebo)","timeFrame":"Day 28"},{"measure":"Safety: Number of Participants With Solicited AEs for Reactogenicity","description":"Occurrence and intensity of solicited AEs for nasal/respiratory and systemic reactogenicity through 7 days following vaccination by treatment group (BPZE1 and placebo)","timeFrame":"Day 7"},{"measure":"Safety: Number of Participants With Treatment Emergent Adverse Events","description":"Occurrence and intensity of TEAEs through 28 days following study vaccination and following challenge by treatment group (BPZE1 and placebo)","timeFrame":"Day 28"},{"measure":"Safety: Number of Participants With TEAEs Related to Vaccination or Related to Challenge","description":"Occurrence and intensity of TEAEs related to vaccination from time of vaccination to challenge or related to challenge for 3 months after challenge by treatment group (BPZE1 and placebo)","timeFrame":"Day 60-120 post vaccination and Day 90 post challenge"},{"measure":"Safety: Number of Participants With AESI and SAE","description":"Occurrence, intensity, and relationship to study vaccine of AESIs and SAEs from vaccination through end of study (EOS) by treatment group (BPZE1 and placebo)","timeFrame":"Day 180"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Correctly answer all questions in the questionnaire provided during the consent process to ensure understanding of the study\n2. Willing to refrain from any nasal sprays (including intranasal steroid sprays) and nasal washes not part of the study for 14 days prior to vaccination (Day 0) and for 28 days following vaccination and challenge\n3. Non-smoker at the time of enrolment, has not smoked (or vaped) in the past 7 days prior to vaccination (including marijuana), and is willing not to smoke (or vape; including marijuana) from the time of vaccination throughout the challenge unit phase\n4. Sufficiently vaccinated (per site and local guidelines) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; proof of vaccination required) \\>14 days prior to study vaccination\n5. Able to understand and comply with planned study procedures including admission for virulent challenge for 17 days and willingness to take the curative antibiotic regimen (azithromycin after inoculation with B. pertussis)\n6. Willing to provide written agreement to and abide by infection control rules from challenge until 1 week following completion of azithromycin eradication\n\nExclusion Criteria:\n\n1. Body mass index \\<17 or \\>30 kg/m2\n2. History of being vaccinated against pertussis within 5 years of enrolment\n3. History of never being vaccinated for pertussis in lifetime\n4. A diagnosis of pertussis by laboratory confirmation or by physician diagnosis in the past 5 years\n5. Previously participated in a pertussis challenge study\n6. Screening laboratory values outside of the normal ranges\n7. Existing chronic disorders of lung, kidney, heart, liver, diabetes, immunodeficiency, autoimmune or significant neurologic condition\n8. Use of illicit drugs (excluding marijuana), evidenced by urine toxicology at Screening or a history of drug/alcohol abuse within the past 2 years\n9. History of active cancer (malignancy) in the last 10 years (except for adequately treated non-melanomatous skin carcinoma)\n10. History of Guillain-Barré syndrome (genetic/congenital or acquired)\n11. History of head trauma with potential of cribriform plate fracture within 1 year prior to Day 0\n12. History of nasal or sinus surgery within 6 months or receipt of facial cosmetic fillers within 3 months prior to Day 0 or diagnosis of nasal polyps\n13. Received immunosuppressive therapy or other immune-modifying drugs (including but not limited to systemic corticosteroids, biologics and methotrexate) in the past 6 months, is on scheduled immunosuppressive therapy or is planning to start immunosuppressive therapy during the trial.\n14. Received immunoglobulins or any blood products within 3 months prior to study vaccine administration or planned receipt during the study\n15. Lives in the same home or has routine contact (face to face \\<2 meters) with persons with known immunodeficiency including persons on immunosuppressant therapy, from study vaccination to challenge and for 1 week after exiting the challenge unit\n16. Resides in the same home, works regularly with, or has contact (face to face \\<2 meters), with infants less than 1 year of age, partially immunised infants or pregnant women, adults \\>65 years of age who have not received a dose of acellular pertussis vaccine (e.g. Tdap) within the past 10 years from study vaccination to challenge and for 1 week after exiting the challenge unit\n17. Known hypersensitivity to any component of the study vaccine\n18. Contraindications or allergic to azithromycin, erythromycin or other macrolide antibiotics\n19. Taking medication that may interact with azithromycin (e.g., nelfinavir, warfarin, digoxin and phenytoin)\n20. Inability to adhere to the protocol, visit schedule or sample collection needs (including housing in the challenge unit)\n21. Participation in any other clinical trial for the testing of an unlicensed product during the previous 3 months or planned during the study conduct","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Oxford Vaccine Group","city":"Oxford","country":"United Kingdom","geoPoint":{"lat":51.75222,"lon":-1.25596}},{"facility":"University Hospital Southampton","city":"Southampton","country":"United Kingdom","geoPoint":{"lat":50.90395,"lon":-1.40428}}]},"referencesModule":{"references":[{"pmid":"41344352","type":"DERIVED","citation":"Gbesemete D, Ramasamy MN, Ibrahim M, Hill AR, Raud L, Ferreira DM, Guy J, Dale AP, Laver JR, Coutinho T, Faust SN, Reed TAN, Babbage G, Weissfeld L, Lang W, Locht C, Samal V, Goldstein P, Solovay K, Rubin K, Noviello S, Read RC. Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis. Lancet Microbe. 2025 Dec;6(12):101211. doi: 10.1016/j.lanmic.2025.101211. Epub 2025 Dec 1."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"BPZE1","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nBPZE1: Live attenuated B. pertussis vaccine\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"},{"id":"FG001","title":"Placebo","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nPlacebo: Placebo\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"27"}]},{"type":"Challenged With Virulent B. Pertussis","achievements":[{"groupId":"FG000","comment":"Reasons for Subjects Not Challenged (n=2):\n\n* 1 subject moved out of country\n* 1 subject unable to challenge for personal reasons","numSubjects":"24"},{"groupId":"FG001","comment":"Reasons for Subjects Not Challenged (n=5):\n\n* 2 subjects discontinued from the study before challenge\n* 2 subjects were lost to follow-up\n* 1 subject experienced an unrelated AE","numSubjects":"22"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"25"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"BPZE1","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nBPZE1: Live attenuated B. pertussis vaccine\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"},{"id":"BG001","title":"Placebo","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nPlacebo: Placebo\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"53"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"53"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29.3","spread":"7.77"},{"groupId":"BG001","value":"31.4","spread":"9.16"},{"groupId":"BG002","value":"30.4","spread":"8.49"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"27"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"26"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"42"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"53"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Colonized Following Virulent Challenge","description":"Participants by treatment group (BPZE1 and placebo) colonized on any day (Challenge Day 9, 11 or 14) following virulent challenge as determined by culture.","populationDescription":"Subjects who received an adequate inoculum defined prospectively as challenge dose \\>=0.5x10\\^5 CFU were evaluated.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Challenge Day 9, 11 or 14","groups":[{"id":"OG000","title":"BPZE1","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nBPZE1: Live attenuated B. pertussis vaccine\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"},{"id":"OG001","title":"Placebo","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nPlacebo: Placebo\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"12"}]}]}]},{"type":"SECONDARY","title":"GMFR of Mucosal Anti-pertussis S-IgA Antibody","description":"The geometric mean fold rise (GMFR) of mucosal anti-pertussis S-IgA antibody (whole cell extract \\[WCE\\], FHA, PRN, PT and fimbriae types 2 and 3 \\[FIM2/3\\]) from baseline to Day 28 (BPZE1 and placebo). Secretory IgA to be normalized (\\[specific S-IgA\\]/\\[total S-IgA\\])","populationDescription":"Available baseline and Day 28 samples","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric Mean Fold Rise","timeFrame":"Day 28","groups":[{"id":"OG000","title":"BPZE1","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. Pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nBPZE1: Live attenuated vaccine\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis Challenge Strain: Challenge Strain"},{"id":"OG001","title":"Placebo","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. Pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nPlacebo: Placebo\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis Challenge Strain: Challenge Strain"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"25"}]}],"classes":[{"title":"WCE","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"2.1","upperLimit":"4.7"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.8","upperLimit":"1.3"}]}]},{"title":"FHA","categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"3.0","upperLimit":"8.2"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.8","upperLimit":"1.5"}]}]},{"title":"PRN","categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"2.9","upperLimit":"9.8"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.7","upperLimit":"1.3"}]}]},{"title":"PT","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"1.2","upperLimit":"2.5"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.9","upperLimit":"1.6"}]}]},{"title":"FIM 2/3","categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"4.9","upperLimit":"16.9"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.9","upperLimit":"1.4"}]}]}]},{"type":"SECONDARY","title":"GMFR of Serum IgA Antibody","description":"The GMFR of serum IgA antibody (WCE, FHA, PRN, PT and FIM2/3) from baseline to Day 28 (BPZE1 and placebo)","populationDescription":"Available baseline and Day 28 samples","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric Mean Fold Rise","timeFrame":"Day 28","groups":[{"id":"OG000","title":"BPZE1","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nBPZE1: Live attenuated B. pertussis vaccine\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"},{"id":"OG001","title":"Placebo","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nPlacebo: Placebo\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"25"}]}],"classes":[{"title":"WCE","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"1.9","upperLimit":"3.4"},{"groupId":"OG001","value":"1.2","lowerLimit":"1.0","upperLimit":"1.4"}]}]},{"title":"FHA","categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"2.2","upperLimit":"4.0"},{"groupId":"OG001","value":"1.1","lowerLimit":"1.0","upperLimit":"1.3"}]}]},{"title":"PRN","categories":[{"measurements":[{"groupId":"OG000","value":"3.7","lowerLimit":"2.2","upperLimit":"6.2"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.9","upperLimit":"1.1"}]}]},{"title":"PT","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.1","upperLimit":"2.0"},{"groupId":"OG001","value":"1.1","lowerLimit":"1.0","upperLimit":"1.3"}]}]},{"title":"FIM 2/3","categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"3.1","upperLimit":"8.2"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.1"}]}]}]},{"type":"SECONDARY","title":"GMFR of Serum IgG Antibody","description":"The GMFR of serum IgG antibody (WCE, FHA, PRN, PT and FIM2/3) from baseline to Day 28 (BPZE1 and placebo)","populationDescription":"Available baseline and Day 28 samples","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric Mean Fold Rise","timeFrame":"Day 28","groups":[{"id":"OG000","title":"BPZE1","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nBPZE1: Live attenuated B. pertussis vaccine\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"},{"id":"OG001","title":"Placebo","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nPlacebo: Placebo\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"25"}]}],"classes":[{"title":"WCE","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.3","upperLimit":"1.7"},{"groupId":"OG001","value":"1.1","lowerLimit":"1.0","upperLimit":"1.1"}]}]},{"title":"FHA","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"1.2","upperLimit":"2.2"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.8","upperLimit":"1.2"}]}]},{"title":"PRN","categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"1.9","upperLimit":"5.0"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.8","upperLimit":"1.5"}]}]},{"title":"PT","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.4","upperLimit":"3.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.7","upperLimit":"1.3"}]}]},{"title":"FIM 2/3","categories":[{"measurements":[{"groupId":"OG000","value":"2.9","lowerLimit":"1.9","upperLimit":"4.5"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.7","upperLimit":"1.2"}]}]}]},{"type":"SECONDARY","title":"Safety: Number of Participants With Solicited AEs for Reactogenicity","description":"Occurrence and intensity of solicited AEs for nasal/respiratory and systemic reactogenicity through 7 days following vaccination by treatment group (BPZE1 and placebo)","populationDescription":"Safety analysis set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 7","groups":[{"id":"OG000","title":"BPZE1","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nBPZE1: Live attenuated B. pertussis vaccine\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"},{"id":"OG001","title":"Placebo","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nPlacebo: Placebo\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"27"}]}],"classes":[{"title":"Nasal/Respiratory","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"20"}]}]},{"title":"Systemic","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"16"}]}]}]},{"type":"SECONDARY","title":"Safety: Number of Participants With Treatment Emergent Adverse Events","description":"Occurrence and intensity of TEAEs through 28 days following study vaccination and following challenge by treatment group (BPZE1 and placebo)","populationDescription":"Safety analysis set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 28","groups":[{"id":"OG000","title":"BPZE1","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nBPZE1: Live attenuated B. pertussis vaccine\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"},{"id":"OG001","title":"Placebo","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nPlacebo: Placebo\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}]}]},{"type":"SECONDARY","title":"Safety: Number of Participants With TEAEs Related to Vaccination or Related to Challenge","description":"Occurrence and intensity of TEAEs related to vaccination from time of vaccination to challenge or related to challenge for 3 months after challenge by treatment group (BPZE1 and placebo)","populationDescription":"Safety analysis set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 60-120 post vaccination and Day 90 post challenge","groups":[{"id":"OG000","title":"BPZE1","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nBPZE1: Live attenuated B. pertussis vaccine\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"},{"id":"OG001","title":"Placebo","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nPlacebo: Placebo\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}]}]}]},{"type":"SECONDARY","title":"Safety: Number of Participants With AESI and SAE","description":"Occurrence, intensity, and relationship to study vaccine of AESIs and SAEs from vaccination through end of study (EOS) by treatment group (BPZE1 and placebo)","populationDescription":"Safety analysis set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 180","groups":[{"id":"OG000","title":"BPZE1","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nBPZE1: Live attenuated B. pertussis vaccine\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"},{"id":"OG001","title":"Placebo","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nPlacebo: Placebo\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"27"}]}],"classes":[{"title":"AESI (COVID-19)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"SAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"SAEs and deaths collected through end of study - up to 7 months. Unsolicited AEs collected up to 28 days post-vaccination and 28 days post-challenge.","eventGroups":[{"id":"EG000","title":"BPZE1","description":"Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nBPZE1: Live attenuated B. pertussis vaccine\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain","deathsNumAffected":0,"deathsNumAtRisk":26,"seriousNumAffected":0,"seriousNumAtRisk":26,"otherNumAffected":7,"otherNumAtRisk":26},{"id":"EG001","title":"Placebo","description":"Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. pertussis strain 1917) approximately 60-120 days later. Participants will receive azithromycin for 3 days beginning 14 days after administration of the challenge strain.\n\nPlacebo: Placebo\n\nAzithromycin: Antibiotic\n\nBordetella Pertussis strain 1917 Challenge: Challenge Strain","deathsNumAffected":0,"deathsNumAtRisk":27,"seriousNumAffected":0,"seriousNumAtRisk":27,"otherNumAffected":9,"otherNumAtRisk":27}],"otherEvents":[{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":27}]},{"term":"Rhinorrhea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":27}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":27}]},{"term":"Other","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":26},{"groupId":"EG001","numAffected":5,"numAtRisk":27}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Chief Medical Officer","organization":"ILiAD Biotechnologies","email":"contact@iliadbiotech.com","phone":"800-603-3525"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-03-06","uploadDate":"2024-10-24T21:38","filename":"Prot_000.pdf","size":1499777},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-06-30","uploadDate":"2024-10-24T21:40","filename":"SAP_001.pdf","size":1573340}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-11-19","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D014917","term":"Whooping Cough"}],"ancestors":[{"id":"D001885","term":"Bordetella Infections"},{"id":"D016905","term":"Gram-Negative Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D017963","term":"Azithromycin"}],"ancestors":[{"id":"D004917","term":"Erythromycin"},{"id":"D018942","term":"Macrolides"},{"id":"D061065","term":"Polyketides"},{"id":"D007783","term":"Lactones"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}